An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn growing interest from consumers seeking alternatives to traditional drugs. Researchers say peptide treatments could change approaches to difficult infections, though concerns about consistency persist. The committee's endorsement of four peptides opens the door for more widespread prescribing, even as critics warn of limited evidence. Industry analysts note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.